Bruker’s Energy & Supercon Technologies (BEST) division has inked two supply agreements with leading global radiology manufacturers totaling approximately $500 million in expected future revenues. These contracts will run over multiple years and cover the provision of Bruker’s latest high-performance superconductors, which are critical components in next-generation MRI magnet production. The agreements solidify Bruker’s position as a key supplier in the medical imaging supply chain and contribute to the division’s robust backlog, which has grown by more than 25% year-over-year.

Bruker has completed the purchase of the remaining 60% stake in TOFWERK AG, taking full ownership of the Swiss innovator in ultra-fast time-of-flight mass spectrometry for small-molecule markets. TOFWERK reported approximately $40 million in revenues in 2025 and operates more than 1,000 instruments worldwide. The acquisition enhances Bruker’s applied MS business by adding field-deployable MIP-TOF systems for air quality monitoring, FIB-TOF OEM accessories for electron microscopy, and the DART-TOF-MS platform for high-throughput, chromatography-free analysis. Financial terms were not disclosed.

Analyst forecasts anticipate double-digit EPS growth for Bruker in FY26, driven by a healthier backlog, recovery in academic and biopharma end markets, and expansion of high-margin semiconductor orders. Cost reduction initiatives, improved pricing power and a more favorable business mix are poised to deliver operating margin expansion. Despite these positive catalysts, the stock trades at a discount to both its historical average and peer multiples, presenting a potential upside opportunity for medium-term investors as earnings inflect and M&A-related dilution normalizes.